Yetsea Medical Secures Tens of Millions in Series A+ Funding Led by Yuanpei Puhua to Accelerate Global Commercialization of Ultra-Widefield SLO and Ophthalmic Devices

Investment Circle (ID: pedaily2012) October 22nd, by reporter, recently, Yaoshi (Suzhou) Medical Technology Co., Ltd. (hereinafter referred to as "Yesight")Completed A+ Round Financing of Tens of Millions of Yuan，This round of financing was strategically led by Oriza Hua Yuan, with Haihong Jinli following up.The funds raised will be mainly used to accelerate the marketing of Yesight's core product, the ultra-widefield confocal Scanning Laser Ophthalmoscope (SLO), both in China and internationally, as well as the research and development of multiple innovative ophthalmic optical devices, further solidifying its leading position in the industry.

Yesight is a company focusing on innovation in ophthalmic medical devices, integrating the R&D, production, sales of innovative ophthalmic optical platforms, and AI big data research. The company has a senior technical team with nearly 20 years of experience, comprising experts from Fortune 500 companies and internationally renowned ophthalmic equipment firms. The team has deep expertise in core image processing, optical design, industrialization, and engineering. Currently, the company has established production and R&D centers in Suzhou, Nantong, and Japan.

To address the shortcomings of traditional fundus camera technology, Yesight has developed the "Yetsea" ultra-widefield laser scanning ophthalmoscope series, including the Yetsea100, 200, and 300 models. Building on the foundation of "ultra-widefield and no pupil dilation," the series is progressively advancing towards "intelligence, multi-modality, and high performance," aiming to provide the most suitable solutions for medical institutions at different levels.

In addition, Yesight's original "Any Door" function (patent applied for) can trace back the dynamic images of any part of the color photo, realizing a revolutionary upgrade from 2D static images to animations in fundus diagnosis, providing a new diagnostic and treatment model for fundus diagnosis. Currently, Yesight has started the layout of overseas markets andExclusive Strategic Cooperation Launched with Several Overseas Renowned Technology Listed Companies from Japan and Other Countries to Jointly Expand Ophthalmic Markets in China and Abroad。

Regarding this round of financing,Mr. Haizhou Wu, founder of Yesight, stated:Thank you for the trust and support from Yuanhe Puhua and Haihong Jinli. Yesight is always committed to early diagnosis and treatment of ophthalmic diseases through cutting-edge technology, safeguarding the eye health of the people in China. This round of financing will mainly focus on two core strategic directions: one is to fully accelerate the marketization process of our globally leading ultra-widefield confocal laser scanning ophthalmoscope (Scanning Laser Ophthalmoscope, SLO) product, empowering its excellent diagnostic value to clinical practice rapidly; the other is to continuously deepen the R&D pipeline, focusing on the diagnosis of core ophthalmic diseases such as fundus, anterior segment, and refractive errors, to create multiple high-end ophthalmic diagnostic devices with clear images, easy operation, and stable quality. We firmly believe that the most cutting-edge technology is the cornerstone of industry progress. Yesight hopes to provide more powerful diagnostic tools for clinical practice through advanced ophthalmic equipment technology and contribute to the development of China's ophthalmology industry.

Yuanhe Puhua Partner Hu Yingping stated:The vast ophthalmic market in China urgently needs innovative user experiences and affordable testing products. The founding team of Yesight possesses internationally leading and extensive product experience, combining medical expertise with innovative engineering technology. They have successfully launched the world's leading first-generation product and quickly gained market recognition. We look forward to accompanying the team as they continue to invest in product iteration close to the market, leading the industry in China-produced independent innovation.